Predictive value of diagnostic PET with 68 Ga DOTATATE/TOC in treatment response to peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-DOTATATE/TOC: a systematic review and meta-analysis. (EANM 2026) - Sep 29, 2026 - Abstract #EP-1037; "Studies including patients with NETs treated with 177Lu-DOTATATE/TOC after previous diagnostic PET (68Ga-DOTATATE/TOC)... Diagnostic PET offers robust predictive power for tumor dosimetry and prognostic value in PRRT. Its utility for estimating doses to critical organs is limited when used in isolation, but improves substantially when combined with dynamic, pharmacokinetic, or machine learning models. These findings support the transition toward personalized, prospective dosimetry strategies based on molecular imaging to optimize PRRT planning."
Retrospective data • Review • Genitourinary Neuroendocrine Tumor • Neuroendocrine Tumor • Solid Tumor • SSTR
|
|
A. Blesa Jimenez; Á. Luján Expósito; L. Camacho Berné; V. López Prior; N. Pérez Castro; A. Tembl Ferrairo
|